In this study, we investigated the regulation of FOXM1 expression by estrogen receptor a (ERa) and its role in hormonal therapy and endocrine resistance. FOXM1 protein and mRNA expression was regulated by ERligands, including estrogen, tamoxifen (OHT) and fulvestrant (ICI182780; ICI) in breast carcinoma cell lines. Depletion of ERa by RNA interference (RNAi) in MCF-7 cells downregulated FOXM1 expression. Reporter gene assays showed that ERa activates FOXM1 transcription through an estrogen-response element (ERE) located within the proximal promoter region. The direct binding of ERa to the FOXM1 promoter was confirmed in vitro by mobility shift and DNA pull-down assays and in vivo by chromatin immunoprecipitation (ChIP) analysis. Our data also revealed that upon OHT treatment ERa recruits histone deacetylases to the ERE site of the FOXM1 promoter, which is associated with a decrease in histone acetylation and transcription activity. Importantly, silencing of FOXM1 by RNAi abolished estrogen-induced MCF-7 cell proliferation and overcame acquired tamoxifen resistance. Conversely, ectopic expression of FOXM1 abrogated the cell cycle arrest mediated by the antiestrogen OHT. OHT repressed FOXM1 expression in endocrine sensitive but not resistant breast carcinoma cell lines. Furthermore, qRT-PCR analysis of breast cancer patient samples revealed that there was a strong and significant positive correlation between ERa and FOXM1 mRNA expression. Collectively, these results show FOXM1 to be a key mediator of the mitogenic functions of ERa and estrogen in breast cancer cells, and also suggest that the deregulation of FOXM1 may contribute to anti-estrogen insensitivity.
Introduction
Breast cancer is the second most prevalent cause of cancer death in the western hemisphere and displays a complex aeitology. The forkhead box (FOX) family member FOXM1 was previously reported to be elevated in breast cancer as well as in carcinomas of other origins (Pilarsky et al., 2004) . FOXM1 is expressed in proliferating adult tissues and in response to injury or repair (Korver et al., 1997a, b; Ye et al., 1999; Leung et al., 2001; Wang et al., 2002) . FOXM1 has a critical role in cell cycle progression; expression of FOXM1 increases at G1 to S phase transition, and reaches maximal levels in G2 to M phase, promoting M phase entry (Leung et al., 2001; Laoukili et al., 2005) . FOXM1 controls the expression of cell cycle regulatory proteins, such as cyclin B1 and cyclin D1 (Leung et al., 2001; Wang et al., 2001; Laoukili et al., 2005) , in addition to genes essential for faithful chromosome segregation and mitosis, such as Nek-2, KIF20A, Cdc25B, Aurora B kinase, Survivin, centromere protein A (CENPA) and CENPB (Wang et al., 2005) . Thus, knockdown of FOXM1 with siRNA results in delay in G2 and mitotic spindle defects, and induces mitotic catastrophe.
Previous work has shown that FOXM1 regulates ERa expression in breast cancer cell lines (Madureira et al., 2006) . Consistently, expression of the FOXM1 target cyclin D1 is associated with ERa positivity in breast cancer (Butt et al., 2005) . The strong correlation between the expression patterns of ERa and FOXM1 in breast cancer cells also suggested the possibility that FOXM1 could be an ERa-regulated gene (Madureira et al., 2006) . Consistent with this hypothesis, a cDNA microarray also identified FOXM1 as one of 344 estrogen-responsive genes in breast cancer cells (Cicatiello et al., 2004) . Estrogen is generally considered to be mitogenic (Brunner et al., 1989) , and exerts its action in the mammary epithelial cells primarily via ERa (Ali and Coombes, 2002) . The expression of ERa is a good prognostic factor in breast cancer, as about two-thirds of ERa-positive patients respond to treatment with antiestrogens such as OHT, ICI or aromatase inhibitors (Osborne and McGuire, 1979; Gapinski and Donegan, 1980; Elkak and Mokbel, 2001 ). Treatment of breast cancer cells with anti-estrogens results in cell cycle arrest at the G1/S phase and in some cases, cell death (Lykkesfeldt et al., 1986) . However, approximately half of the patients who initially respond to hormonal therapy develop resistance and relapse, following longterm treatment (Ali and Coombes, 2002; Goss et al., 2008; Yamashita, 2008) . Our previous observation that ERa-positive breast cancer cell lines express higher levels of FOXM1 protein (Madureira et al., 2006) led us to hypothesize that FOXM1 expression is also regulated by ERa. In an effort to elucidate the mechanisms of anti-estrogen action and resistance to endocrine therapy, we investigated the regulation of FOXM1 by ERa and its role in endocrine sensitivity and resistance in breast cancer cells.
Results
ERa ligands modulate the expression of FOXM1 protein and mRNA levels To investigate whether the FOXM1 protein and mRNA levels are regulated by ERa, the ERa-positive breast cancer cell lines ZR-75-1 and MCF-7 and ERa-negative line MDA-MB-231 were treated with the ERa ligands E2, OHT and ICI for the times indicated and harvested for western blotting and qRT-PCR analysis. Treatment of estrogen-starved ZR-75-1 and MCF-7 cells with E2 enhanced the expression of FOXM1 protein and mRNA ( Figure 1) . Within 8 h of E2 treatment, FOXM1 protein and mRNA levels peaked and remained high for at least 48 h. By contrast, E2 treatment did not cause significant changes in either FOXM1 protein or mRNA levels in the ERa-negative control MDA-MB-231 cells. Treatment of both the ZR-75-1 and MCF-7 cells with the partial antagonist OHT resulted in a reduction in FOXM1 protein levels that was noticeable within 4 h, reaching minimal levels within 24 h post-treatment. Yet again, treatment with OHT had little effect on the expression of FOXM1 protein and mRNA in MDA-MB-231 cells. Similar to OHT, incubation with the pure antagonist ICI, which causes the degradation of ERa, resulted in a reduction in the FOXM1 expression, with both the protein and mRNA levels completely vanished within 24 h post-treatment. We also studied the ability of OHT or ICI to antagonize E2-regulated FOXM1 upregulation, and the result showed that the effects of OHT or ICI following E2 stimulation are similar to those under normal growth conditions (Supplementary Figure S1 ). In summary, the FOXM1 protein and mRNA levels were upregulated by ERa agonists and downregulated by ERa antagonists in ERa-positive, but not ERa-negative breast cancer cell lines, suggesting that FOXM1 is regulated by ERa.
The FOXM1 promoter responds to ERa and ligands To investigate if the regulation of FOXM1 by ERa is at the promoter level, ERa-negative COS-1 cells were transiently transfected with the ERa expression construct pHEGO, with a luciferase reporter gene under the control of the proximal 2.4 kb FOXM1 promoter (WT-Trident), or its truncation mutants HindIII (1.4 kb), and ApaI (300 bp) (Figure 2a ). We observed a twofold increase of the WT-Trident FOXM1-luc activity after E2 treatment, and this induction by E2 was repressed in the presence of OHT (Figure 2a ). The highest increase (2.7-fold) by E2 was observed for the ApaI-luc activity (Figure 2a) . The HindIII-luc activity was upregulated to a lesser extent (1.5-fold) by E2 (Figure 2a) . The response of the FOXM1 promoter to ERa was further verified by co-transfection of COS-1 cells with titrated amounts of pHEG0 and the WTTrident-luc or ApaI-luc reporter plasmids (Figure 2a ). Both the WT-Trident and ApaI promoters were induced in a dose-dependent manner by increasing amounts of ERa in the presence of E2 (Figure 2a) . It is notable that the control pS2 promoter showed maximum E2-stimulation with very low levels of ERa expression, supporting the notion that pS2 may be one of the most E2-sensitive genes (Masiakowski et al., 1982) . Collectively, these results indicate that the ApaI truncation is the minimal proximal FOXM1 promoter responsive to ERa, consistent with a previous study identifying a similar region of the FOXM1 promoter that responds to serum stimulation (Korver et al., 1997a) .
The ERE-like element at À45 bp of the FOXM1 promoter confers responsiveness to ERa ligands Analysis using the Transcription Element Search System (TESS,http://www.cbil. upenn.edu/cgi-bin/tess/tess) (Schug, 2008) revealed an ERE-like element (Bourdeau et al., 2004) located at À45 bp from the transcription start site. We next focused our studies on the characterization of the ERE-like element at À45 bp in the ApaI promoter fragment and introduced point mutations using site-directed mutagenesis by base-substitution in both arms of the ERE-like palindrome of the ApaI truncation (Bourdeau et al., 2004) (Figure 2b ). For comparison, a single point mutation that does not grossly disrupt the ERE-consensus was also introduced in one arm of the ERE-like element in mERE1 (Figure 2b ). The activity of the wild-type as well as the mutated ApaI-luc constructs mERE1, mERE3 and mERE4 was examined by co-transfection assays in COS-1 cells with and without pHEG0, in the presence or absence of E2 (Figure 2b) . The results showed that the mERE1-luc construct showed similar responsiveness to ERa and E2 induction as the wild-type ApaI-luc. In contrast, both the mERE3-luc and mERE4-luc mutants lost the majority of their responsiveness to E2 (Figure 2b ). Together these co-transfection results indicate that the ERE-like element located at À45 bp confers the responsiveness to ERa, further confirming that FOXM1 is a target gene of ERa.
ERa binds directly to the ERE-like element of the FOXM1 promoter in vitro We next tested the in vitro binding of ERa to the ERElike site by electrophoretic mobility shift assay with nuclear lysate from MCF-7 cells. From the electrophoretic mobility shift assay, it was clear that ERa binds to the wild-type ERE-like site of ApaI, but not the mutated mERE3 site (Figure 3a ). This complex of ERa and WT ERE biotin-oligonucleotide was further supershifted with a specific anti-ERa antibody, indicating that the complex contains ERa (Figure 3a ). This ERa complex could be competed off by excess amounts of a classical consensus ERE oligonucleotide, but not by a mERE3 ApaI site oligonucleotide. Finally, unlabelled Figure 1 Expression of FOXM1 and ERa in response to E2, OHT and ICI treatments in breast cancer cell lines. ZR-75-1, MCF-7 and MDA-MB-231 cells were cultured in 5% double-charcoal striped FCS and phenol red-free medium for 24 h before stimulated with E2. Breast cancer cells cultured in 10% FCS and phenol red medium were also treated with OHT or ICI. At times indicated, cells were collected and analysed for FOXM1, ERa and tubulin expression by western blotting. FOXM1 mRNA levels of these cells were also analysed by qRT-PCR, and normalized with L19 RNA expression. Total RNA (2 mg) isolated using the RNeasy Mini kit (Qiagen, Crawley, UK) was reverse transcribed using the Superscript III reverse transcriptase and random primers (Invitrogen, Paisley, UK), and the resulting first strand cDNA was used as template in the real-time PCR. All experiments were performed in triplicate. The following gene-specific primer pairs were designed using the ABI Primer Express software: FOXM1-sense: 5 0 -TGCAGCTAGGGAT GTGAATCTTC-3 0 and FOXM1-antisense: 5 0 -GGAGCCCAGTCCATCAGAACT-3 0 ; ERa-sense: 5 0 -CAGATGGTCAGTGCCTTG TTGG-3 0 and ERa-antisense: 5 0 -CCAAGAGCAAGTTAGGAGCAAACAG-3 0 ; L19-sense 5 0 -GCGGAAGGGTACAGCCAAT-3 0 and L19-antisense 5 0 -GCAGCCGGCGCAAA-3 0 . Specificity of each primer was determined using NCBI BLAST module. Real time PCR was performed with ABI PRISM 7700 Sequence Detection System using SYBR Green Mastermix (Applied Biosystems, Brackley, UK). The qRT-PCR results shown are representative of three independent experiments.
ERa regulates FOXM1 expression in breast cancer J Millour et al FOXM1 WT ERE oligonucleotide was successful in competing off the ERa binding on the consensus ERE oligonucleotide. To show that ERa binds to the ERElike site of ApaI we used the biotin-labelled oligonucleotides in pull-down assays. ERa binding was analysed by immunoblotting with an anti-ERa antibody. As shown in Figure 3b , ERa had much higher affinity for the wildtype ERE than the mutant mERE3. ERa-binding to the FOXM1 ERE could be competed away by molar excess of wild-type ERE, but not the mutant mERE. We next extended our pull-down assays to MCF-7 and ZR-75-1 cells in the absence or presence of OHT, ICI and E2 Figure S2) . The results confirmed our previous data that both OHT and ICI inhibit ERa activity, whereas ICI, but not OHT, represses ERa expression. In the pull-downs, ERa binding on the biotin-WT ERE was effectively competed by 10 Â molar excess of unlabelled WT ERE, and not mERE3, oligonucleotides. We also probed for the recruitment of HDAC to the ERE site upon OHT, ICI or E2 treatment in MCF-7 cells, and the results revealed that HDAC2 was recruited to the ERE site upon OHT but not ICI or E2 treatment ( Figure 3c ). Taken together these results showed that ERa binds specifically to the ERE-like element of the FOXM1 promoter in vitro and that HDAC is recruited to the ERE site upon OHT treatment.
ERa and HDAC bind specifically on the ERE-like element of ApaI in vivo We further tested the in vivo binding of ERa on the FOXM1 promoter in the MCF-7 and ZR-75-1 cell lines by chromatin immunoprecipitation assays (ChIP), following treatment of the cells with either OHT or ICI ( Figure 3d ). The DNA immunoprecipitated by an anti-ERa antibody was amplified using the FOXM1 ERE primers to show in vivo binding of ERa on the ERE-like site of FOXM1 promoter at À45 bp, in agreement with the in vitro results. Occupancy of FOXM1 promoter by ERa was enhanced in ZR-75-1, but not MCF-7 cells following treatment with OHT, and a reduction in ERa binding was observed in MCF-7 and ZR-75-1 cells following treatment with ICI. The ChIP assays also showed that upon OHT treatment there was an increase in HDAC1 and HDAC2 recruitment and a corresponding decrease in acetylated histones H3 and H4 associated with the FOXM1 promoter, indicating that OHT treatment caused the recruitment of HDAC, which confers transcriptional repression to the ERE region of the FOXM1 promoter (Figure 3e ).
Significant positive correlation between FOXM1 and ERa mRNA levels in breast cancer patient samples To determine the clinical relevance of the relationship between ERa and FOXM1 expression, we analysed the FOXM1 and ERa mRNA levels in 69 frozen archival clinical samples, of which 21 were from benign disease patients, 39 from patients with breast tumours and nine from healthy individuals (Supplementary Figure S3) . Preliminary studies showed that despite FOXM1 mRNA expression being associated with tumour status, grade, size and menopausal status, the differences were not significant, possibly reflecting the relatively small sample size (Supplementary Figure S4) . Analysis of unadjusted data revealed no significant correlation between the expression levels of FOXM1 and ERa mRNA ( Figure 4a ). This is not entirely unexpected as high levels of FOXM1 mRNA expression (upper quartile) have previously been shown to be associated with breast cancer progression, poor prognosis and endocrine resistance in a number of microarray studies (Martin et al., 2008) . We next re-evaluated the data qafter excluding patient samples with high levels of FOXM1 expression. By leaving out patient samples with FOXM1 mRNA levels above the 75th percentile value (FOXM1/L19 mRNA ¼ 40.700) (Figure 4b ), we found a significant correlation between FOXM1 and ERa mRNA expression ( Figure 4c ). In cases where there were high levels of FOXM1 mRNA expression, we also found that FOXM1 expression is independent of ERa mRNA levels, suggesting FOXM1 is no longer regulated by ERa (Figure 4d ). These results validate our tissue culture findings in breast patient samples, confirming the crucial relationship between ERa and FOXM1 expression. In breast cancer samples with high FOXM1 expression, the relationship between ERa and FOXM1 mRNA expression is uncoupled, suggesting ERa no longer controls FOXM1 expression. This also supports the conjecture that uncoupling of the regulation of FOXM1 by ERa may have a role in endocrine resistance.
ERa silencing downregulates FOXM1 expression whereas FOXM1 knock-down inhibits estrogen-induced cell proliferation To provide further evidence for the regulation of FOXM1 by ERa, we investigated the effect of ERa silencing on FOXM1 expression in proliferating MCF-7 cells. As shown in Figure 5a , the ERa siRNA effectively knocked down the expression of ERa, which in turn also resulted in a downregulation of FOXM1 at the protein (Figure 5b ). This is in agreement with our previous finding that FOXM1 regulates ERa expression (Madureira et al., 2006) . The results of the cell proliferation assay showed that FOXM1 silencing completely abolished the mitogenic effects of E2 in the ERa-positive MCF-7 cells, indicating that FOXM1 is essential for the estrogen-dependent growth of MCF-7 cells, and mediates the proliferative function of ERa (Figure 5b ). To investigate the potential role of FOXM1 in hormonal resistance, we silenced FOXM1 expression using siRNA in the MCF-7 TAM R4 cells, an OHTresistant MCF-7 clone (Lykkesfeldt et al., 1986 (Lykkesfeldt et al., , 1994 , and studied its effects on cell proliferation (Figure 5c ). Interestingly, the proliferation assays showed that the MCF-7 TAM R4 was responsive to E2 re-stimulation, and knockdown of FOXM1 decreased the ability of E2 to induce the proliferation of the MCF-7 TAM R4 cells. Notably, these cells with FOXM1 knockdown cultured in the absence or presence of E2 had the same proliferation rate as steroid-depleted cells, suggesting E2 targets FOXM1 to induce proliferation in this system. In addition, our data also showed that OHT could antagonize the proliferative function of E2, and that FOXM1 knockdown could be combined with OHT to cause further decreases in the rate of cell proliferation. Together these results clearly show that the knockdown of FOXM1 sensitizes the resistant cells to OHT and diminishes the responsiveness to E2. Dysregulated FOXM1 is associated with breast cancer endocrine resistance As FOXM1 is essential for ERa's proliferative function, uncoupling FOXM1 from ERa regulation could result in resistance to endocrine therapy in breast cancer cells. To test this hypothesis, we studied the expression of FOXM1 in hormone sensitive as well as resistant MCF-7 cells, after treatment with OHT (Figure 6a) , were also included as controls. Western blot analysis revealed that the FOXM1 level declined in the parental MCF-7 cells on treatment with OHT, but not in the resistant cells or MCF-7 cells expressing the deregulated FOXM1. Consistently, the expression of FOXM1 targets, including Polo-like kinase-1 (PLK-1) Figure 3 ERa binds directly to the ERE on the FOXM1 promoter. (a) Biotinylated wild-type ERE or the mutant ERE3 oligonucleotides were incubated with MCF-7 cell lysates in the presence or absence of 10 Â molar excess of non-biotinylated ERE3 or consensus ERE oligonucleotides or an anti-ERa antibody. In brief, gel shift assays (20 ml total volume) contained 3 ı`g nuclear extracts and 50 ng/ml poly (dI-dC) in 1 Â binding buffer and 20 pmol unlabelled oligonucleotides. For the supershifts, 1 ml of the anti-ERa (Santa Cruz; H222) antibody were included in the reaction mix. The mixtures were pre-incubated at room temperature for 15 min, followed by addition of 100 fmol of biotin-labelled double-stranded estrogen response element (ERE-conc. 5 0 -GCCGATTGGCGA CGTTCGGTCACGCTGACCTTAACGCTCCGCCGGCG-3
, and incubation at room temperature for 20 min, followed by a 30-min incubation on ice. Protein-DNA complexes were separated on 5% 0.5 Â TBE polyacrylamide gels. The electrophoretic transfer of the binding reactions to the nylon membrane, and the detection of the biotin labelled DNA by chemiluminescence, were performed according to the PIERCE kit's protocols. (b) Nuclear extracts from MCF-7 cells were incubated with biotinylated oligonucleotides representing region of the FOXM1 promoter containing the ERE or the mutated ERE3 site in the absence or presence of molar excess of non-biotinylated ERE3 or consensus ERE oligonucleotides. Proteins binding to the biotinylated oligonucleotides were pulled-down using streptavidine agarose beads and analysed by western blot using specific antibodies as indicated. (c) The nuclear extracts (Supplementary Figure S1 ) from MCF-7 and ZR-75-1 cells with or without OHT or ICI for 24 h were also examined by pull-down assays using biotinylated wild-type or mutant (mERE3) oligonucleotides as described above. (d) Chromatin immunoprecipitation (ChIP) analysis of the human FOXM1 promoter. MCF-7 and ZR-75-1 cells untreated or treated with ICI or OHT for 24 h were used for ChIP assays using IgG, anti-ERa antibodies as indicated. After crosslink reversal, the co-immunoprecipitated DNA was amplified by PCR using primers amplifying the FOXM1 ERE containing region (À184/ þ 4) and a control region (À1157/À1257), and resolved in 2% agarose gel. (e) MCF-7 untreated or treated with OHT for 24 h were used for ChIP assays using IgG antibodies against acetylated H3 and H4, HDAC1 and HDAC2 as described above. Representative data from three independent experiments are shown.
ERa regulates FOXM1 expression in breast cancer J Millour et al and CDC25B, mirrored the expression patterns of FOXM1 in the three MCF-7 cell lines. It is notable that there were no significant changes in either the ERa or the endogenous FOXM1 in the OHT-resistant cell line and the MCF-7 harbouring the active FOXM1. This is likely to be due to the positive feedback mechanism between ERa and FOXM1, described here and previously (Madureira et al., 2006) . In agreement with the western blot results, qRT-PCR analysis showed that OHT repressed FOXM1 mRNA expression in MCF-7 cells but not in the MCF-7-TAM R4 and MCF-7-DN-FOXM1 cells. The western blot results also showed that cyclin A and not its catalytic partner CDK2 was downregulated by 48 h in MCF-7 cells, and the decline in cyclin A levels occurred in a comparatively slower kinetics in TAM R4 and DN-FOXM1 cells. Consistent with this, the CDK2 activity-specific pRB(Thr821) antibody showed that the repression of cyclin A/E-CDK2 activity coincided with the downregulation of cyclin A expression in these MCF-7 cells. Given that cyclin A-CDK2 phosphorylation of FOXM1 can activate its transcriptional activity (Wierstra and Alves, 2006a; Park et al., 2008; Laoukili et al., 2008a, b) , this finding suggests another potential mechanism by which FOXM1 activity can be downregulated by OHT. As cyclin A and -E functions downstream of cyclin D1, (Fung and Poon, 2005; Myatt and Lam, 2007; Tashiro et al., 2007) , which is a transcription target of FOXM1, it is likely that the constitutively active DN-FOXM1 upregulates cyclin D1 to sustain cyclin A expression and G1 to S cell cycle phase progression upon OHT treatment in the DN-FOXM1 MCF-7 cells. Consistent with this, the western blot analysis showed that the cyclin D1 level and its associated activity revealed by the CDK4/6 phospho-pRB(Ser807/811) antibody were overexpressed in the DN-FOXM1-and maintained in the TAM R4 -MCF-7 cells. In addition, ectopic expression of FOXM1 also increases the expression levels of cyclin D1 in both MCF-7 (Supplementary Figure S5) and MDA-MB-231 cells (Supplementary Figure S6) . Given the well-documented role of cyclin D1 in endocrine resistance (Lundgren et al., 2008; Wang et al., 2008; Finn et al., 2009; Yamashita et al., 2009; Zwart et al., 2009 ) and G1/S transition (Fung and Poon, 2005; Myatt and Lam, 2007; Tashiro et al., 2007) , our data also support a role for FOXM1 in mediating breast cancer endocrine sensitivity and resistance at least in part through modulating cyclin D1 expression. We performed cell cycle analysis of the MCF-7, MCF-7TAM R4 and MCF-7 DN-FOXM1 cells following treatment with OHT ( Figure 6c) . The results showed that OHT caused a predominantly G1 cell cycle arrest in the parental MCF-7 cells, but had comparatively little effects on the cell cycle distribution of the MCF-7TAM R4 and MCF-7 DN-FOXM1 cells. We also generated MCF-7 cells stably transfected with the wild-type FOXM1 (MCF-7-FOXM1) and studied the effects of OHT on the transfected pool as well as individual clones of MCF-7-FOXM1 cells (Supplementary Figure S5) . Western blot analysis showed that overexpression of the full-length FOXM1 prevented the downregulation of FOXM1 targets such as CDC25b and PLK in response to tamoxifen treatment. The cell cycle analysis showed that these cells underwent the cell cycle arrest at G1, concommitant with FOXM1 downregulation, at a slower kinetics compared with MCF-7 cells transfected with the empty vector. This further suggests that downregulation of FOXM1 is important for the G1/S arrest and that FOXM1 may also be regulated by tamoxifen at post-transcriptional levels. Collectively, these results indicate that FOXM1 has a role in mediating the anti-proliferative effects of OHT via ERa, and that its deregulated expression contributes towards the development of endocrine resistance. 
Discussion
Expression of ERa expression in breast cancer cell lines is regulated by FOXM1 (Madureira et al., 2006) . In this study, we investigated the reciprocal regulation of FOXM1 expression by ERa. Using breast carcinoma cell lines, we showed that FOXM1 protein and mRNA expression are regulated by ER-ligands, including E2, OHT and ICI. We also found that depletion of ERa by RNA interference in MCF-7 cells leads to downregulation of FOXM1 expression. Using reporter gene assays, we showed that ERa activates FOXM1 transcription through an ERE located at À45 bp upstream of the transcriptional start site (Bourdeau et al., 2004) . The direct binding of ERa to the FOXM1 promoter was confirmed in vitro by mobility shift and DNA pull-down assays, and in vivo by ChIP analysis. Importantly, silencing of FOXM1 by RNA interference abolishes estrogen-mediated MCF-7 cell proliferation and overcomes tamoxifen resistance in 'acquired resistant' MCF-7 cells. Conversely, ectopic expression of a constitutively active FOXM1 can abrogate the cell cycle arrest mediated by OHT. Collectively, the results presented clearly confirm FOXM1 as a key mediator of the mitogenic functions of ERa and estrogen in breast cancer cells.
To address the physiological significance of our finding, we studied the FOXM1 mRNA expression and its relationship to ERa mRNA level in the breast cancer biopsy samples. After the exclusion of the data with high levels of FOXM1 expression (upper 25th percentile), a statistically significant correlation between ERa and FOXM1 mRNA expression was detected. This is in agreement with a recent breast cancer patient microarray data set analysis indicating that high levels of FOXM1 mRNA expression (upper 25th percentile) are associated with poor prognosis in breast cancer (Martin et al., 2008) . The discordance between ERa and FOXM1 mRNA expression in patient samples with high FOXM1 expression probably indicates that in these subjects FOXM1 expression is deregulated with their control of FOXM1 transcription by ERa overridden by other mitogenic signals or genetic changes. Our findings that OHT represses FOXM1 expression in endocrine sensitive but not resistant breast carcinoma cell lines, and that ectopic expression of FOXM1 can abrogate the anti-proliferative effects of OHT, further confirm that deregulation of FOXM1 may contribute to anti-estrogen insensitivity. The observation that there were no significant changes in the ERa or the endogenous FOXM1 levels in the MCF-7 cells expressing the active FOXM1 highlights an important positive feedback mechanism between ERa and FOXM1, described here and previously (Madureira et al., 2006) . This makes FOXM1 a particularly critical ERa target gene in breast cancer development and endocrine resistance, as the feedback loop will amplify the mitogenic action of estrogens. It is likely this positive feedback transcriptional mechanism is uncoupled in ERa-negative breast cancer, as ERa overexpression does not induce FOXM1 Figure S6) . Previous studies have shown that changes in epigenetic regulation, such as DNA methylation and histone acetylation, are responsible in silencing of the ERa gene in ER-negative human breast cancer cells (Yan et al., 2003) . We also speculate that recruitment of ERa to target genes in vivo might require 'pioneering factors, such as FOXA1, which are deregulated in ERa-negative cells (Carroll et al., 2005; Carroll and Brown, 2006) . This positive feedback transcriptional mechanism may also account for the significant association between ERa and FOXM1 mRNA observed in breast tissue samples. Consistently, FOXM1 is one of eight overexpressed genes identified in solid tumours by comparison of different microarray data sets (Pilarsky et al., 2004) . In conclusion, our results indicate that FOXM1 is a downstream target of ERa. Our findings also provide potential insights into the mechanism of anti-estrogen action and endocrine resistance, and show that ER regulation of FOXM1 may also contribute to anti-estrogen responsiveness.
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